INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Open-market purchaseVerified data
SM

Schmitt Daniel M bought ACTU

Director, President, CEO and Director · ACTUATE THERAPEUTICS, INC. · Common Stock

Side
BUY
Value
$50K
Shares
140.8K
Price
$0.36
Executed
Oct 28, 2026
Disclosed
Oct 29, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Oct 28 executedOct 29, 2026 disclosed

ACTU · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
37/ 100 · ELEVATED
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+9 / 25

    $50K reported value · 46.7% of prior position

Filing timing0 / 15

Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ACTU

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    82.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    195.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    87.7K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    368.3K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    126.2K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    65.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    824.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    682.9K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    195.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    87.7K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    682.9K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    368.3K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    48.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    36.1K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    82.5K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    133.1K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    824.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    126.2K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    82.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    269.3K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001683168-26-008147
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 28, 2026
    Published
    Oct 29, 2026
    Ingested by INSIDER
    Nov 5, 02:08 UTC
    Last re-read
    Nov 5, 02:08 UTC

    Extracted facts

    Filer
    Schmitt Daniel M
    Role
    Director, President, CEO and Director
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    ACTUATE THERAPEUTICS, INC.
    Ticker
    ACTU
    Shares
    140.8K
    Price per share
    $0.36
    Value
    $50,000
    Execution date (reported)
    Oct 28, 2026
    Owned after transaction
    442.6K shares
    Days from execution to publication
    1

    Calculation

    Value = shares × reported price per share

    • Shares: 140.8K
    • Price: $0.355

    = $50,000

    What this establishes

    Schmitt Daniel M filed this Form 4 reporting a open-market purchase of ACTU on Oct 28, 2026. It became public on Oct 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President, CEO and Director
    Schmitt Daniel Mcik:0001318470
    Issuer
    ACTUATE THERAPEUTICS, INC.cik:0001652935

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.